ANTI-IgE gene therapy
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 21, 2002
app pub date -
Nov 20, 2001
filing date -
Sep 16, 1998
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Disclosed are gene constructs of anti-IgE antibodies or fragments thereof for therapy for allergic diseases. Upon introduction into suitable host, anti-IgE antibody gene constructs will direct the synthesis of an antibody (or its fragments) capable of binding to free IgE in serum but not binding to IgE bound to the high affinity receptor (Fc.epsilon.RI), or not binding to IgE bound to both the high affinity receptor and the low affinity receptor (Fc.epsilon.RII or CD23). The antibody (or fragments) which are synthesized may also inhibit IgE binding to the high affinity receptor or the low affinity receptor, or to both.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully